Clinicopathological characteristics of the discovery data set
| Non-responder (N=113) | Responder (N=101) | P value | |
| Gender | |||
| Male | 85 (75.2%) | 91 (90.1%) | 0.007 |
| Female | 28 (24.8%) | 10 (9.9%) | |
| Age | |||
| Mean (SD) | 58.7 (12.5) | 57.5 (14.6) | 0.543 |
| BMI | |||
| Mean (SD) | 21.4 (3.01) | 21.8 (2.95) | 0.430 |
| Missing | 3 (2.7%) | 1 (1.0%) | |
| ECOG | |||
| 0–1 | 99 (87.6%) | 96 (95.0%) | 0.08984 |
| ≥2 | 14 (12.4%) | 5 (5.0%) | |
| Smoking status | |||
| Never smoked | 63 (55.8%) | 36 (35.6%) | 0.002 |
| Current or former smoker | 46 (40.7%) | 63 (62.4%) | |
| Missing | 4 (3.5%) | 2 (2.0%) | |
| Smoking package year | |||
| Mean (SD) | 15.0 (22.3) | 18.9 (24.4) | 0.226 |
| Missing | 1 (0.9%) | 1 (1.0%) | |
| Tumor histologic type | |||
| LUAD | 86 (76.1%) | 79 (78.2%) | 0.747 |
| LUSC | 27 (23.9%) | 22 (21.8%) | |
| Pathological stage | |||
| III | 9 (8.0%) | 12 (11.9%) | 0.004 |
| IVA | 30 (26.5%) | 47 (46.5%) | |
| IVB | 74 (65.5%) | 42 (41.6%) | |
| LOT | |||
| First line | 23 (20.4%) | 42 (41.6%) | < 0.001 |
| Second line or more | 90 (79.6%) | 59 (58.4%) | |
| ICIs | |||
| Anti PD-1 | 98 (86.7%) | 80 (79.2%) | 0.149 |
| Anti PD-L1 | 15 (13.3%) | 21 (20.8%) | |
BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; ICIs, immune checkpoint inhibitors; LOT, line of therapy; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PD-1, programmed death-1; PD-L1, programmed cell death-ligand 1.